Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

4SC Discovery Receives €450K Epigenetic Research Grant

Published: Tuesday, April 15, 2014
Last Updated: Tuesday, April 15, 2014
Bookmark and Share
4SC Discovery GmbH will receive a EUR 450,000 grant from the EU for the research of new compounds targeting cardiovascular diseases such as stroke.

Using this grant 4SC can apply its key epigenetic expertise in drug discovery and development, which the company had so far been focusing primarily on oncology, also in the field of cardiovascular diseases.

The collaboration of 4SC Discovery, the Medical Clinic of the University of Munich and other companies and academic working groups was launched recently and is scheduled to run for about three years. The main collaboration partner of 4SC Discovery is Prof. Dr. med. Martin Dichgans, Director of the Institute for Stroke and Dementia Research (ISD) of the Medical Clinic of the University of Munich. The grant is part of the EU consortium "CVgenes-at-target" (Grant Agreement Number: 601456) for the purpose of researching new therapeutic target structures for the treatment of cardiovascular diseases caused by an inflammatory reaction of the blood vessels. This project, which involves twelve partners in Europe, will be coordinated by Prof. Dr. Heribert Schunkert from the German Heart Centre in Munich.

4SC Discovery has already started its work of identifying and optimising highly potent, selective compounds against a new epigenetic target molecule. The company will perform part of the compound screening, medicinal chemistry and the optimisation of the compounds' pharmacokinetics and solubility. Preclinical trials with the compounds will be conducted at the Medical Clinic of the University of Munich to deliver the first proofs-of-concept. 4SC Discovery will retain the rights to the identified substances.

During the first part of the collaboration, the focus will be on researching the investigated epigenetic molecule as a possible therapeutic target structure for stroke. Epigenetic target structures such as histone deacetylases (HDACs) coordinate gene transcription and therefore play an important role in the development of cancer and neurological diseases. It will now be researched what role epigenetic modifications play in cardiovascular diseases. During the second part of the collaboration, additional target structures that potentially play a role in stroke development will be subjected to a compound screening and potential inhibitors will be identified and optimised.

Stroke is a consequence of cardiovascular diseases and the third most frequent cause of death in Germany. A recently conducted analysis of the global study entitled "Global Burden of Disease" published in the renowned medical journal Lancet in January of 2014 showed that the number of younger people suffering from stroke is increasing. This is caused by risk factors such as high blood pressure, smoking, high blood sugar, lack of exercise and an unbalanced diet. In 2010, about 16.9 million people worldwide suffered a stroke and 5.9 million of them died as a result.

Dr. Daniel Vitt, Managing Director of 4SC Discovery GmbH and Chief Scientific Officer at 4SC AG, commented: "While cardiovascular diseases were not a focus for 4SC in the past, we have built a comprehensive knowledge base regarding the effective inhibition of HDAC molecules based on our epigenetic research especially in the field of cancer. As a result, we are now also viewed as a competent partner in other therapeutic areas in which epigenetic molecules play an important role. We are pleased to start another collaboration with renowned partners such as the Medical Clinic of the University of Munich and to be able to make a contribution in the discovery of new compounds. Apart from the scientific aspect, EU funding for our activities also represents an attractive economic incentive."

Prof. Dr. med. Martin Dichgans, Director of the Institute for Stroke and Dementia Research (ISD) at the Medical Clinic of the University of Munich, added: "It is our objective to advance research in the field of stroke and dementia and to make a contribution to the development of entirely new treatment options. 4SC Discovery is the ideal partner for us in terms of epigenetic issues and the practical implementation of early-stage research."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Retractable Protein Nanoneedles
The ability to control the transfer of molecules through cellular membranes is an important function in synthetic biology; a new study from researchers at Harvard’s Wyss Institute for Biologically Inspired Engineering and Harvard Medical School (HMS) introduces a novel mechanical method for controlling release of molecules inside cells.
Iron in the Blood Could Cause Cell Damage
Concentrations of iron similar to those delivered through standard treatments can trigger DNA damage within 10 minutes, when given to cells in the laboratory.
Advancing Synthetic Biology
Living systems rely on a dizzying variety of chemical reactions essential to development and survival. Most of these involve a specialized class of protein molecules — the enzymes.
Insights into the Function of the Main Class of Drug Targets
About thirty percent of all medical drugs such as beta-blockers or antidepressants interact with certain types of cell surface proteins called G protein coupled receptors.
Honey’s Potential to Save Lives
The healing powers of honey have been known for thousands of years.
Muscles on-a-Chip
This study may help explain why stem cell-based therapies have so far shown limited benefits for heart attack patients in clinical trials.
3-D Printed Lifelike Liver Tissue for Drug Screening
A team led by engineers at the University of California, San Diego has 3D-printed a tissue that closely mimics the human liver's sophisticated structure and function. The new model could be used for patient-specific drug screening and disease modeling.
Envigo Rat Models Proven to be Susceptible to Intra-Vaginal HSV-2 Infection and Protectable
Scientific findings establish the effectiveness of new approach to investigate the protective effects of vaccine candidates and anti-viral microbodies and to study asymptomatic primary genital HSV-2 infection.
Valvena, GSK Sign New R&D Collaboration
Valneva to supply process development services for EB66® -based Influenza vaccines.
Food Triggers Creation of Regulatory T Cells
IBS researchers document how normal diet establishes immune tolerance conditions in the small intestine.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!